Automated triage · 24-hour turnaround
A fast, automated first read on one company: six independent signals, each linked to its source records. Built on a substrate of 3,900+ biomedical companies and 4.7 million records from 34 public sources, including FDA, SEC, ClinicalTrials.gov, NIH, CMS and USPTO.
What You Receive
Each signal is reported on its own, with the records it rests on. There is no composite score and no go/no-go verdict: you decide what the signals mean for your decision.
What the FDA record shows: clearances, approvals, recalls and enforcement actions.
What the trial registries and literature show: registered studies, their status and results.
What the patent record shows: filings and the assignees on them.
What CMS sources show about coverage and coding in the company's space.
What public filings and records show about the people leading the company.
Comparable companies in the same space and what their records show.
The Quick Screen is fully automated. It is produced from public data sources and what you tell us on the intake form, and it is not individually reviewed by a physician or an engineer before delivery. Physician and biomedical-engineer review is part of the full reports below.
How It Works
Step 1
Pay $5,000 by card through Stripe's secure checkout.
Step 2
Tell us which company to screen and anything we should know. Go to the intake form.
Step 3
Delivered within 24 hours of a complete intake.
Questions before you buy? Book a 20-minute call.
Going Deeper
Your Quick Screen fee credits in full toward any larger Vantage engagement. Full reports cover eight domains (regulatory, clinical, IP, reimbursement, commercial, team, financial and competitive) and are reviewed by a physician and a biomedical engineer.
Diligence on your own company, in 48 hours, with a 30-minute debrief.
The Founder Report plus the investor-readiness annex, in 48 hours, with a physician debrief.
For an investment decision on a single company, in 48 hours, with a physician debrief.
For corporate development: the Diligence Report plus integration risk and reference-contact review, with a 60-minute strategy session.
Commercialization-readiness review for one university-held asset or spinout.
Per-company diligence for a program, read against its cohort.